CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Kuo Hua Tung; Cheng Wei Lin; Chun Chen Kuo; Li Tzu Li; Ya Hsun Kuo; Chung Wu Lin; Han Chung Wu

doi:10.1016/j.canlet.2012.12.001

CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Kuo Hua Tung, Cheng Wei Lin, Chun Chen Kuo, Li Tzu Li, Ya Hsun Kuo, Chung Wu Lin, Han Chung Wu

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

Original language	English
Pages (from-to)	58-67
Number of pages	10
Journal	Cancer Letters
Volume	331
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2012.12.001
Publication status	Published - Apr 30 2013
Externally published	Yes

Keywords

Angiogenesis
Clathrin heavy chain
HIF-1α
Monoclonal antibody
Pancreatic cancer

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2012.12.001

Cite this

@article{b627b37b551c4648994bc9b67c2f737b,

title = "CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling",

abstract = "Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.",

keywords = "Angiogenesis, Clathrin heavy chain, HIF-1α, Monoclonal antibody, Pancreatic cancer",

author = "Tung, {Kuo Hua} and Lin, {Cheng Wei} and Kuo, {Chun Chen} and Li, {Li Tzu} and Kuo, {Ya Hsun} and Lin, {Chung Wu} and Wu, {Han Chung}",

year = "2013",

month = apr,

day = "30",

doi = "10.1016/j.canlet.2012.12.001",

language = "English",

volume = "331",

pages = "58--67",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

AU - Tung, Kuo Hua

AU - Lin, Cheng Wei

AU - Kuo, Chun Chen

AU - Li, Li Tzu

AU - Kuo, Ya Hsun

AU - Lin, Chung Wu

AU - Wu, Han Chung

PY - 2013/4/30

Y1 - 2013/4/30

N2 - Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

AB - Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

KW - Angiogenesis

KW - Clathrin heavy chain

KW - HIF-1α

KW - Monoclonal antibody

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84873522077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873522077&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.12.001

DO - 10.1016/j.canlet.2012.12.001

M3 - Article

C2 - 23228632

AN - SCOPUS:84873522077

SN - 0304-3835

VL - 331

SP - 58

EP - 67

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this